Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA) was founded in 2010, formerly known as Sienna Labs, Inc., changed its current name in February 2016, and is headquartered in California, USA State Westlake Village, with 43 full-time employees (6/30/2017), is a biopharmaceutical company that discovers, develops and commercializes topical products for the medical dermatology and beauty markets in North America.
Sienna Biopharmaceuticals (SNNA):
Siena Biopharmaceutical Company is a clinical-stage biopharmaceutical company, focusing on introducing biotechnology innovations into the fields of medical dermatology and aesthetics, thereby discovering, developing and commercializing first-class, targeted and dedicated (medical beauty) products .
Sienna Biopharmaceuticals products include:
- The company’s main product candidate, SNA-120, a TrkA inhibitor, is in phase IIb clinical development for the treatment of pruritus and neurogenic inflammation associated with psoriasis.
- SNA-125, a dual JAK3/TrkA inhibitor, is currently in the preclinical research stage for the treatment of atopic dermatitis, psoriasis and pruritus.
- SNA-001, a photosensitive drug therapy for treating acne vulgaris and reducing premature gray hair, is currently in pivotal clinical trials (pivotal clinical trials).
Sienna Biopharmaceuticals (SNNA) investment:
Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA) was listed on Nasdaq on 7/27/2017 IPO, with an issue price of US$15 and 4,333,333 shares issued, raising US$64,999,995, stock code: SNNA.